Clinical Prior Authorization Update for Dupixent Scheduled for August 13, 2020

Clinical Prior Authorization Update for Dupixent Scheduled for August 13, 2020

VDP routinely updates existing clinical prior authorization criteria to reflect recent FDA-approved indications or safety information from the product package insert. FirstCare will revise the Dupixent (dupilumab) clinical prior authorization on August 13, 2020:

  • Current criteria allow prescribing for patients age 12 and older with moderate to severe atopic dermatitis
  • Revised criteria will allow prescribing for age 6 and older
For FirstCare clinical edits please click here.

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.